Ontology highlight
ABSTRACT:
SUBMITTER: Echevarria-Vargas IM
PROVIDER: S-EPMC5938620 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Echevarría-Vargas Ileabett M IM Reyes-Uribe Patricia I PI Guterres Adam N AN Yin Xiangfan X Kossenkov Andrew V AV Liu Qin Q Zhang Gao G Krepler Clemens C Cheng Chaoran C Wei Zhi Z Somasundaram Rajasekharan R Karakousis Giorgos G Xu Wei W Morrissette Jennifer Jd JJ Lu Yiling Y Mills Gordon B GB Sullivan Ryan J RJ Benchun Miao M Frederick Dennie T DT Boland Genevieve G Flaherty Keith T KT Weeraratna Ashani T AT Herlyn Meenhard M Amaravadi Ravi R Schuchter Lynn M LM Burd Christin E CE Aplin Andrew E AE Xu Xiaowei X Villanueva Jessie J
EMBO molecular medicine 20180501 5
Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS-mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpressed in NRAS-mutant melanoma and that high levels of the BET family member BRD4 are associated with poor patient survival. Combining BET and MEK inhibitors synergistically curbed the growth of <i>NRAS</i ...[more]